Report
Hyloris Pharma - Busy year ahead with doubling of revenue expected
*This morning, HYL released it FY23 results, most notably announcing a 44% increase in its product revenue (equal contribution of Maxigesic IV and Sotalol IV) to EUR 2.8m vs. FY22 (EUR 1.2m at H1 '23). Significant further ramp-up this year with at least doubling of product revenue expected mainly driven by commercial rollout of Maxigesic IV in the USA. *Modest increase in R&D expected in 2024. Cash position expected to provide runway for next 18-24 months. 30 assets by 2025 strategy reiterated.*We will finetune our estimates following this release and come back with an update shortly. We reiterate our Buy
Underlying
Hyloris Pharmaceuticals
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.